EA200870052A1 - Фармацевтические препаративные формы эсциталопрама модифицированного и пульсирующего высвобождения - Google Patents
Фармацевтические препаративные формы эсциталопрама модифицированного и пульсирующего высвобожденияInfo
- Publication number
- EA200870052A1 EA200870052A1 EA200870052A EA200870052A EA200870052A1 EA 200870052 A1 EA200870052 A1 EA 200870052A1 EA 200870052 A EA200870052 A EA 200870052A EA 200870052 A EA200870052 A EA 200870052A EA 200870052 A1 EA200870052 A1 EA 200870052A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- modified
- disorder
- escital
- pulsating
- premium
- Prior art date
Links
- 208000019906 panic disease Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 abstract 1
- 229960004341 escitalopram Drugs 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Настоящее изобретение относится к фармацевтическим препаративным формам эсциталопрама модифицированного и пульсирующего высвобождения и их применению для лечения расстройств центральной нервной системы, включая расстройства настроения (например, большое депрессивное расстройство) и тревожные расстройства (например, генерализованное тревожное расстройство, социальное тревожное расстройство, посттравматическое стрессовое расстройство и паническое расстройство, включая панические приступы).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75084105P | 2005-12-14 | 2005-12-14 | |
PCT/US2006/062064 WO2007070840A2 (en) | 2005-12-14 | 2006-12-14 | Modified and pulsatile release pharmaceutical formulations of escitalopram |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200870052A1 true EA200870052A1 (ru) | 2008-10-30 |
Family
ID=38163632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200870052A EA200870052A1 (ru) | 2005-12-14 | 2006-12-14 | Фармацевтические препаративные формы эсциталопрама модифицированного и пульсирующего высвобождения |
Country Status (12)
Country | Link |
---|---|
US (1) | US20070134322A1 (ru) |
EP (1) | EP1962831A4 (ru) |
JP (1) | JP2009519969A (ru) |
KR (1) | KR20080081924A (ru) |
CN (1) | CN101330913A (ru) |
AU (1) | AU2006325768A1 (ru) |
CA (1) | CA2633909A1 (ru) |
EA (1) | EA200870052A1 (ru) |
IL (1) | IL191691A0 (ru) |
NO (1) | NO20083034L (ru) |
WO (1) | WO2007070840A2 (ru) |
ZA (1) | ZA200804597B (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
GR20080100696A (el) * | 2008-10-23 | 2010-05-13 | Genepharm �.�. | Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης |
CN102920664B (zh) * | 2012-11-27 | 2013-10-02 | 臧杰 | 一种长效口服胰岛素缓控释微球的制备方法 |
CN104523638B (zh) * | 2014-11-28 | 2020-02-21 | 浙江华海药业股份有限公司 | 含有草酸艾司西酞普兰的片剂及其制备方法 |
WO2018190294A1 (ja) * | 2017-04-10 | 2018-10-18 | 東和薬品株式会社 | エスシタロプラム医薬組成物 |
WO2018206923A1 (en) * | 2017-05-11 | 2018-11-15 | Opal Ip Limited | Novel formulations |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070051953A (ko) * | 1998-11-02 | 2007-05-18 | 엘란 코포레이션, 피엘씨 | 다입자 변형 방출 조성물 |
AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
AU7405000A (en) * | 1999-09-28 | 2001-04-30 | H. Lundbeck A/S | Melt granulated composition and modified release dosage form prepared from said composition |
GB0018968D0 (en) * | 2000-08-02 | 2000-09-20 | Pfizer Ltd | Particulate composition |
MEP5908A (xx) * | 2001-05-01 | 2010-02-10 | Lundbeck & Co As H | Upotreba enantiomerno čistog escitaloprama |
RS8304A (en) * | 2001-07-31 | 2006-12-15 | H.Lundbeck A/S. | Crystalline composition containing escitalopram |
US20040132826A1 (en) * | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
WO2005044262A1 (en) * | 2003-10-29 | 2005-05-19 | Wyeth | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof |
DK2210605T3 (en) * | 2003-11-04 | 2017-05-22 | Tcd Royalty Sub Llc | Daily single dose doses of trospium. |
CA2556216A1 (en) * | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
US20050250838A1 (en) * | 2004-05-04 | 2005-11-10 | Challapalli Prasad V | Formulation for sustained delivery |
CA2626025A1 (en) * | 2005-10-14 | 2007-04-26 | Forest Laboratories, Inc. | Stable pharmaceutical formulations containing escitalopram and bupropion |
-
2006
- 2006-12-13 US US11/610,194 patent/US20070134322A1/en not_active Abandoned
- 2006-12-14 KR KR1020087014412A patent/KR20080081924A/ko not_active Application Discontinuation
- 2006-12-14 AU AU2006325768A patent/AU2006325768A1/en not_active Abandoned
- 2006-12-14 EA EA200870052A patent/EA200870052A1/ru unknown
- 2006-12-14 JP JP2008545969A patent/JP2009519969A/ja active Pending
- 2006-12-14 CN CNA2006800471728A patent/CN101330913A/zh active Pending
- 2006-12-14 EP EP06840255A patent/EP1962831A4/en not_active Withdrawn
- 2006-12-14 CA CA002633909A patent/CA2633909A1/en not_active Abandoned
- 2006-12-14 ZA ZA200804597A patent/ZA200804597B/xx unknown
- 2006-12-14 WO PCT/US2006/062064 patent/WO2007070840A2/en active Application Filing
-
2008
- 2008-05-25 IL IL191691A patent/IL191691A0/en unknown
- 2008-07-09 NO NO20083034A patent/NO20083034L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2007070840A3 (en) | 2007-11-01 |
EP1962831A4 (en) | 2013-01-09 |
IL191691A0 (en) | 2008-12-29 |
JP2009519969A (ja) | 2009-05-21 |
CN101330913A (zh) | 2008-12-24 |
WO2007070840A2 (en) | 2007-06-21 |
WO2007070840A8 (en) | 2008-06-26 |
KR20080081924A (ko) | 2008-09-10 |
US20070134322A1 (en) | 2007-06-14 |
AU2006325768A1 (en) | 2007-06-21 |
ZA200804597B (en) | 2009-08-26 |
CA2633909A1 (en) | 2007-06-21 |
NO20083034L (no) | 2008-07-09 |
EP1962831A2 (en) | 2008-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2007000015A (es) | Usos terapéuticos de inhibidores de rtp801 | |
EA201071243A1 (ru) | Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом | |
EA200700333A1 (ru) | Терапевтические применения ингибиторов rtp801 | |
EA201491592A1 (ru) | Соединения индолов и индазолов, активирующие ampk | |
EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
EA201000006A1 (ru) | Способы и композиции для лечения аллергических заболеваний | |
EA201071045A1 (ru) | Соединения оксадиазоантрацена для лечения диабета | |
ECSP077894A (es) | Antagonistas de npy, preparación y usos | |
ECSP067021A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
EA201071264A1 (ru) | Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера | |
EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
MX2007009356A (es) | Compuestos y composiciones como moduladores de ppar. | |
ATE478072T1 (de) | Spiroimidazol-derivate als ppar-modulatoren | |
EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
ECSP067019A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
ATE445624T1 (de) | Verbindungen und zusammensetzungen als ppar- modulatoren | |
EA201500403A1 (ru) | Соединения, активирующие теломеразу, и способы их применения | |
EA200870052A1 (ru) | Фармацевтические препаративные формы эсциталопрама модифицированного и пульсирующего высвобождения | |
CR10062A (es) | Composiciones y metodos de tratamiento para trastornos del sistema nervioso central | |
EA200801081A1 (ru) | Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона | |
BRPI0820668A2 (pt) | Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina | |
EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
MA32224B1 (fr) | Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales |